Engbaek H C, Heckscher T, Højgaard C, Larsen S O, Rasmussen K N, Vergmann B
Eur J Respir Dis. 1982 Mar;63(2):84-93.
A total of 577 Danish patients with tuberculosis were observed for a period of 5 years. A primary phase of treatment with 300 mg Isoniazid (INH), 450 mg Rifampicin (RMP) and 1200 mg Ethambutol (EMB) daily for 3 months was followed by administration of either INH+RMP or INH+EMB for 12 or 18 months after conversion. During the initial period the number of bacteria decreased rapidly, even in patients with the most severe tuberculosis, and all patients became culture negative. There was no significant difference in efficacy of RMP and EMB in the secondary phase. One of the 577 patients again became positive during the follow-up period, but there were no bona fide cases of relapse among patients who completed the treatment.
对总共577名丹麦结核病患者进行了为期5年的观察。初始治疗阶段为每日服用300毫克异烟肼(INH)、450毫克利福平(RMP)和1200毫克乙胺丁醇(EMB),持续3个月,之后在转阴后给予INH+RMP或INH+EMB治疗12或18个月。在初始阶段,即使是最严重的结核病患者,细菌数量也迅速减少,所有患者的培养结果均转为阴性。在第二阶段,RMP和EMB的疗效没有显著差异。577名患者中有1名在随访期间再次呈阳性,但完成治疗的患者中没有真正的复发病例。